Pacing impedance variability in tined steroid eluting leads

Impact of magnetic resonance imaging on functional integrity of non-conditional cardiovascular implantable electronic devices

BACKGROUND

Cardiovascular implantable electronic devices (CIEDs) have historically restricted the use of magnetic resonance imaging (MRI) due to the potential clinical and configurational risks associated with electromagnetic interference. In this study, the authors investigated the impact of MRI on the functional integrity of non-conditional CIEDs and their clinical correlates.

METHODS

In this prospective, observational single-center study, we enrolled patients undergoing MRI over a 5-year period. Prior to assessing the impact of MRI on CIEDs, we performed interrogations in sequential duplication to assess the intrinsic variability of devices. Subsequently, we performed interrogations immediately after MRI, and monitored changes in device parameters and clinical events.

RESULTS

We completed 492 MRI studies, 58% in patients with permanent pacemakers (PPMs) and 42% with implantable cardioverter defibrillators (ICDs). Subsequent MRI exposures occurred in 15% encounters. Accounting for intrinsic variability in CIED leads, there were no significant changes in RA, RV, or LV parameters after MRI, regardless of the region imaged (thoracic vs. non-thoracic), type of CIED (PPMs vs. ICDs) and among those with serial MRIs. When ranked for % change pre- to post-MRI, the majority of RA, RV, and LV metrics for thresholds, sensing, and impedance conformed to ≤20% change from baseline. No significant clinical adverse cardiac events or effect on device microcircuitry occurred during the study.

CONCLUSION

Incorporating a novel reproducibility tactic, there were neither clinically meaningful device parameter changes nor adverse clinical events during or following MRIs, suggesting the effects of MRI on non-conditional CIED integrity are far less than previously perceived.

Safety of Magnetic Resonance Imaging in Patients with Cardiac Devices

BACKGROUND

Patients who have pacemakers or defibrillators are often denied the opportunity to undergo magnetic resonance imaging (MRI) because of safety concerns, unless the devices meet certain criteria specified by the Food and Drug Administration (termed "MRI-conditional" devices).

METHODS

We performed a prospective, nonrandomized study to assess the safety of MRI at a magnetic field strength of 1.5 Tesla in 1509 patients who had a pacemaker (58%) or an implantable cardioverter-defibrillator (42%) that was not considered to be MRI-conditional (termed a "legacy" device). Overall, the patients underwent 2103 thoracic and nonthoracic MRI examinations that were deemed to be clinically necessary. The pacing mode was changed to asynchronous mode for pacing-dependent patients and to demand mode for other patients. Tachyarrhythmia functions were disabled. Outcome assessments included adverse events and changes in the variables that indicate lead and generator function and interaction with surrounding tissue (device parameters).

RESULTS

No long-term clinically significant adverse events were reported. In nine MRI examinations (0.4%; 95% confidence interval, 0.2 to 0.7), the patient's device reset to a backup mode. The reset was transient in eight of the nine examinations. In one case, a pacemaker with less than 1 month left of battery life reset to ventricular inhibited pacing and could not be reprogrammed; the device was subsequently replaced. The most common notable change in device parameters (>50% change from baseline) immediately after MRI was a decrease in P-wave amplitude, which occurred in 1% of the patients. At long-term follow-up (results of which were available for 63% of the patients), the most common notable changes from baseline were decreases in P-wave amplitude (in 4% of the patients), increases in atrial capture threshold (4%), increases in right ventricular capture threshold (4%), and increases in left ventricular capture threshold (3%). The observed changes in lead parameters were not clinically significant and did not require device revision or reprogramming.

CONCLUSIONS

We evaluated the safety of MRI, performed with the use of a prespecified safety protocol, in 1509 patients who had a legacy pacemaker or a legacy implantable cardioverter-defibrillator system. No long-term clinically significant adverse events were reported. (Funded by Johns Hopkins University and the National Institutes of Health; ClinicalTrials.gov number, NCT01130896 .).

Effect of insulation material in aging pacing leads: comparison of impedance and other electricals: time-dependent pacemaker insulation changes

BACKGROUND

There has been concern over declining bipolar (BP) impedance (Z) in aging polyurethane (PU) cardiac pacing leads. Subsequently, a prospective study was conducted comparing BP Z, threshold (Th), and R-wave sensing amplitude of 55D PU-insulated (Model 4024, Medtronic, Inc., Minneapolis, MN, USA) and silicone-insulated (Model 5024) leads.

METHODS

This study was initiated by The Iowa Heart Center. Patients with Model 4024 (N = 162) or 5024 (N = 120) pacing leads with at least 6 years implant time were enrolled and followed for an additional 5 years.

RESULTS

There was a significant drop in the mean BP Z for the Model 4024 population, between enrollment (6 years) and the final endpoint (11 years), which was in contrast to the Model 5024 which did not see a significant drop in its mean BP Z for this same period. The trend difference seen in the means between the two models was statistically significant (P < 0.0001). In addition, a statistically significant relationship was found between dropping BP Z and rising Th (P < 0.0001). The analysis showed that if BP Z dropped below 200 ohms, the probability of having a >3X increase over baseline, in Th at 2.5 V, increases from approximately 3-7% to as high as 30%.

CONCLUSIONS

A significant drop in BP Z observed in the PU-insulated Model 4024 lead was not present in the silicone-insulated Model 5024 lead. The statistically significant relationship between dropping BP Z and rising Th helps to understand how to better manage patients with aging leads.

A prospective evaluation of a protocol for magnetic resonance imaging of patients with implanted cardiac devices

BACKGROUND

Magnetic resonance imaging (MRI) is avoided in most patients with implanted cardiac devices because of safety concerns.

OBJECTIVE

To define the safety of a protocol for MRI at the commonly used magnetic strength of 1.5 T in patients with implanted cardiac devices.

DESIGN

Prospective nonrandomized trial. (ClinicalTrials.gov registration number: NCT01130896) SETTING: One center in the United States (94% of examinations) and one in Israel.

PATIENTS

438 patients with devices (54% with pacemakers and 46% with defibrillators) who underwent 555 MRI studies.

INTERVENTION

Pacing mode was changed to asynchronous for pacemaker-dependent patients and to demand for others. Tachyarrhythmia functions were disabled. Blood pressure, electrocardiography, oximetry, and symptoms were monitored by a nurse with experience in cardiac life support and device programming who had immediate backup from an electrophysiologist.

MEASUREMENTS

Activation or inhibition of pacing, symptoms, and device variables.

RESULTS

In 3 patients (0.7% [95% CI, 0% to 1.5%]), the device reverted to a transient back-up programming mode without long-term effects. Right ventricular (RV) sensing (median change, 0 mV [interquartile range {IQR}, -0.7 to 0 V]) and atrial and right and left ventricular lead impedances (median change, -2 Ω [IQR, -13 to 0 Ω], -4 Ω [IQR, -16 to 0 Ω], and -11 Ω [IQR, -40 to 0 Ω], respectively) were reduced immediately after MRI. At long-term follow-up (61% of patients), decreased RV sensing (median, 0 mV, [IQR, -1.1 to 0.3 mV]), decreased RV lead impedance (median, -3 Ω, [IQR, -29 to 15 Ω]), increased RV capture threshold (median, 0 V, IQR, [0 to 0.2 Ω]), and decreased battery voltage (median, -0.01 V, IQR, -0.04 to 0 V) were noted. The observed changes did not require device revision or reprogramming.

LIMITATIONS

Not all available cardiac devices have been tested. Long-term in-person or telephone follow-up was unavailable in 43 patients (10%), and some data were missing. Those with missing long-term capture threshold data had higher baseline right atrial and right ventricular capture thresholds and were more likely to have undergone thoracic imaging. Defibrillation threshold testing and random assignment to a control group were not performed.

CONCLUSION

With appropriate precautions, MRI can be done safely in patients with selected cardiac devices. Because changes in device variables and programming may occur, electrophysiologic monitoring during MRI is essential.

Variation in Pacing Impedance: Impact of Implant Site and Measurement Method

BACKGROUND

Variations in pacing impedance may be observed during implantation of various active fixation pacing leads. However, these variations can be influenced by the nature of the fixation, the implant site, or the measurement method. Here we describe implant dynamics for a 4.1F, catheter-delivered pacemaker lead.

METHODS

Endocardial active fixation leads were implanted under direct intracardiac visualization in two right atrial sites and three right ventricular sites in isolated swine (n = 6) and human (n = 4) hearts. Impedance measurements were recorded at each site employing three different measurement techniques-Pacing System Analyzer (PSA) 5311, PSA 2090, and the Impedance Tone Box (Medtronic, Inc., Minneapolis, MN, USA)-with four different degrees of lead fixation: helix touching, one turn fixed (1 TF), two turns fixed (2 TF), and overtorqued.

RESULTS

Pacing impedances increased from touching to 1 TF to 2 TF at all implant sites in both swine and human hearts. Overtorquing applied to leads was associated with visible distortion at the endocardial tissue-lead interface in at least 60% of swine (18 of 30 implants) and human hearts (nine of 14 implants). Impedance values in the right atrial high septum were significantly larger than in any other implant site (P < 0.05). The three measurement methods did not yield significantly different impedance measurements.

CONCLUSIONS

Variations in measured impedances were associated with the nature of implant fixation at all sites in both swine and human hearts.

Underestimation of Pacing Threshold as Determined by an Automatic Ventricular Threshold Testing Algorithm

In this case report, we describe markedly different pacing thresholds determined by a manual threshold test and the automatic Ventricular Capture Management algorithm. The discrepancy in pacing threshold values reported was due to the difference in the AV intervals used with the different testing methods. We propose that the differences in right ventricular dimensions with altered diastolic filling periods affected the threshold in this patient with a new passive fixation lead in the right ventricular apex.

High Pacing Impedances: Are You Overtorquing Your Leads?

BACKGROUND

Variations in measured pacing impedances that occur at the time of lead implantation remain largely unexplained and may be due to the morphology of the tissue-lead interface.

METHODS

An endocardial pacing lead was implanted under direct endoscopic visualization and parameters were measured for defined stages of implantation into multiple sites within the right atrium of in vitro swine hearts (n = 6, 38 implants), in vivo swine hearts (n = 2, 10 implants), and an in vitro human heart (n = 1, 15 implants).

RESULTS

Steady increases in impedance values up to 2 turns fully fixed (2TF) were associated with minimal tissue distortion in all implants. Overtorquing of the in vitro swine implants resulted in severe distortion at the tissue-lead interface demonstrating either tissue wrapping (24 implants) or tissue coring (14 implants). Impedance and threshold values remained elevated (953 +/- 282 Omega, 7.86 +/- 3.0 V; both P < 0.05 vs 2TF) during tissue distortion/wrapping, while tissue-cored implants were associated with significant decreases (552 +/- 187 Omega, 6.2 +/- 2.2 V; both P < 0.05 vs 2TF). P-wave amplitudes demonstrated no significant changes or correlation to tissue distortion. Importantly, both swine in vivo and human in vitro data demonstrated similar trends compared with the swine in vitro data.

CONCLUSIONS

In this study, one is able to directly observe and correlate the degree of distortion at the tissue-lead interface with measured electrical parameters. Instantaneous impedance values obtained during fixation serve as a superior indicator of an acceptable lead implantation, and should therefore be carefully monitored during implantation.

A Novel Ex Vivo Heart Model for the Assessment of Cardiac Pacing Systems

Background: Advances in endocardial device design have been limited by the inability to visualize the device-tissue interface. The purpose of this study was to assess the validity of an isolated heart approach, which allows direct ex vivo intracardiac visualization, as a research tool for studying endocardial pacing systems. Method of approach: Endocardial pacing leads were implanted in the right atria and ventricles of intact swine (n=8) under fluoroscopic guidance. After collection of pacing and sensing performance parameters, the hearts were excised with the leads intact and reanimated on the isolated heart apparatus, and parameters again recorded. Results: Atrial ex vivo parameters significantly decreased compared with in vivo measurements: P-wave amplitudes by 39%, slew rates by 61%, and pacing impedances by 42% (p<0.05 for each). Similarly, several ventricular ex vivo parameters decreased: R-wave amplitudes by 39%, slew rates by 62%, and pacing impedances by 31%. In contrast, both atrial (4.4±2.8 vs 3.3±2.8V; p=ns) and ventricular thresholds increased (1.2±0.7 vs 0.6±0.1V; p<0.05 for all). Three distinct phenomena were observed at the lead-tissue interface. Normal implants (70%) demonstrated minimal tissue distortion and resulted in elevated impedance and threshold values. Three implants (13%) resulted in severe tissue distortion and/or tissue wrapping and were associated with highly elevated pacing parameters. Tissue coring occurred in four implants (17%) where the lead would spin freely in the tissue after overtorquing of the lead. Conclusions: The utility of the isolated heart approach was demonstrated as a tool for the design and assessment of the performance of endocardial pacing systems. Specifically, the ability to visualize device-heart interactions allows new insights into the impact of product design and clinical factors on lead performance and successful implantation.

Pacing threshold trends and variability in modern tined leads assessed using high resolution automatic measurements: conversion of pulse width into voltage thresholds

With the aid of an algorithm for automatic pacing threshold (T) measurement in the atrium and ventricle, downloadable into implanted Thera pacemakers (Medtronic Inc.), we studied T evolution during lead maturation, T variation during activities of daily living, and various types of beat-to-beat T variations in three tined bipolar leads: 5.6-mm2 steroid-eluting (Medtronic Inc. models 4524 atrial-J [n = 8] and 4024 ventricular [n = 8]), 1.2-mm2 steroid-eluting (Medtronic Inc. models 5534 atrial-J [n = 9] and 5034 ventricular [n = 9]), and 8-mm2 without steroid (Intermedics models 432-04 atrial-J [n = 7] and 430-10 ventricular [n = 7]). The leads were implanted in 24 consecutive patients with intact AV conduction (required by the algorithm) and followed for up to 13-25 months after implantation. Since the algorithm determined pulse width Ts at different amplitudes that, depending upon T level, could range from 0.5 to 5.0 V, we invented a methodology for conversion of pulse width Ts into voltage Ts at 0.5 ms, to pool and present T data on a universal scale. Frequent, high resolution T measurements revealed details on the lead maturation process that we divided into three stages: initial T subsiding, first wave of T peaking, and a new, quicker or slower, T rise. Although there were notable differences in duration and magnitude of T peaking on the individual basis, differences between the three lead types and between the atrium and ventricle were demonstrable. The 1.2-mm2 leads exhibited less T peaking than their predecessors 5.6-mm2 leads and excellent positional stability, whereas 8-mm2 leads demonstrated the most intensive T peaking and highest mean chronic T values. T changes during activities of daily living showed some tendencies-higher T during night and lower T during exercise--yet with a number of exceptions. The overall magnitude of daily T fluctuations was < 0.2 V in all but one lead, and 50% daily voltage safety margin would be sufficient. A 100% voltage safety margin may be inadequate for a 1-year period during the chronic phase (after 6 months of implantation). A scheme for calculation of pulse width safety margins equivalent to voltage safety margins is given. Some leads can exhibit very large beat-to-beat T variations before, during, and after T peaking, and prospective algorithms for automatic T measurement should verify T values through more than 1-2 captured beats to obviate a great underestimation of the T providing consistent capture. T dependence upon pacing rate was negligible. Consistent-capture hysteresis may, in conjunction with lead instability, be as much as 0.25 V. Therefore, it is better to use an incremental approach from below to T level during automatic T measurements.

Taking advantage of sophisticated pacemaker diagnostics

The ever-increasing complexity of pacing systems, combined with functions that vary from one manufacturer to another, can pose challenges during analysis of device function. Standard pacemaker diagnostics are measured data, electrogram telemetry, maker annotations and event counters, albeit with their current limitations. New diagnostic features discussed include time-based diagnostics, histograms of sensed amplitudes, pacing thresholds, or impedance trending. Mode-switching algorithms, combined with diagnostic features, facilitate the use of dual-chamber devices in patients with paroxysmal atrial tachyarrhythmias. The introduction of electrogram storage into pacemakers further improves diagnostic capabilities and allows a permanent validation and optimization of diagnostic and therapeutic algorithms. External diagnostic devices, which provide Holter recordings with continuous marker annotations and patient-triggered diagnostics, are additional features that will become increasingly important.

Clinical use of low output settings in 1.2-mm2 steroid eluting electrodes: three years of experience

A new generation of tined steroid-eluting leads featuring 1.2-mm2 distal electrodes (CapSure Z, Medtronic Inc., Minneapolis MN, USA) has the potential to reduce battery current drain and enhance pulse generator longevity by means of high pacing impedance and low pacing threshold. Forty patients aged 50-87 years (mean 72.4 years) were implanted with 33 ventricular (models 4033 and 5034) and 30 atrial-J (models 4533 and 5534) leads with 1.2-mm2 electrodes. Low pacing outputs, mainly in the range from 1 V/0.20 ms to 1.6 V/0.36 ms with > or = 3:1 pulse width safety margins (PWSM) applied, were instituted at 3-6 months of implantation and adjusted at subsequent follow-up controls according to changes in thresholds. Cumulative follow-up period of low outputs was 1,512 months (24 months per lead, range 9-36 months), which involved 3.43 follow-up controls per lead (range 2-5). During follow-up, pulse width thresholds (PWTs) at the used amplitudes did not change in 55.5% of the leads; PWTs increased by < or = 100% in 36.5%, by 101%-200% in 1.6%, and by > 200% in 6.3% of the leads. Changes in PWT that would apparently exceed 3:1 PWSM over a 1-year period occurred in one atrial lead where even the nominal 3.5 V/0.4-ms output would not be effective and in one ventricular lead in the aftermath of an acute myocardial infarction (300% PWT rise at 1.6 V). Based on the present observations, pacemaker dependent patients require > or = 4:1 PWSM and other patients > or = 3:1 PWSM with output pulse widths < or = 0.60 ms and annual pacemaker clinic visits. Calculated battery current drain and anticipated longevity associated with a variety of pacing outputs and impedances are provided, compared, and discussed. Correlation between acute and chronic pacing impedances and pacing thresholds was weak, implying that a systematic intraoperative pacing site optimization cannot contribute significantly to the extension of average battery longevity.